[Therapeutic aspects of metabolic effects of xylitol in diabetics].
D000090:Acetoacetates / Q000037:antagonists & inhibitors; D000438:Alcohols / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005230:Fatty Acids, Nonesterified / Q000037:antagonists & inhibitors; D005990:Glycerol / Q000097:blood; D006801:Humans; D007263:Infusions, Parenteral; D007657:Ketone Bodies / Q000037:antagonists & inhibitors; D007773:Lactates / Q000097:blood; D050356:Lipid Metabolism; D008055:Lipids / Q000037:antagonists & inhibitors; D008297:Male; D008875:Middle Aged; D011773:Pyruvates / Q000097:blood; D013997:Time Factors; D014280:Triglycerides / Q000037:antagonists & inhibitors; D014993:Xylitol / Q000008:administration & dosage / Q000627:therapeutic use
D000090:Acetoacetates; D000438:Alcohols; D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007657:Ketone Bodies; D007773:Lactates; D008055:Lipids; D011773:Pyruvates; D014280:Triglycerides; D005990:Glycerol; D014993:Xylitol
Therapeutische Aspekte der Stoffwechselwirkungen von Xylit bei Diabetikern.